List of Excipients in Branded Drug ORPHENADRINE CITRATE ASPIRIN CAFFEINE

Generic Drugs Containing ORPHENADRINE CITRATE ASPIRIN CAFFEINE

Company	Ingredient	NDC	Excipient
Jerome Stevens Pharmaceuticals Inc	orphenadrine citrate, aspirin, caffeine	50564-554	D&C YELLOW NO. 10
Jerome Stevens Pharmaceuticals Inc	orphenadrine citrate, aspirin, caffeine	50564-554	FD&C BLUE NO. 1
Jerome Stevens Pharmaceuticals Inc	orphenadrine citrate, aspirin, caffeine	50564-554	LACTOSE

What are the Most Frequently-Used Excipients in ORPHENADRINE CITRATE ASPIRIN CAFFEINE?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1
1	LACTOSE

Last updated: August 2, 2026

The commercial opportunity for orphenadrine citrate, aspirin, and caffeine is primarily a low-cost prescription combination strategy rather than a new-chemical-entity or patent-led opportunity. The strongest value levers are tablet manufacturability, gastrointestinal tolerability, dose flexibility, packaging, supply reliability, and differentiation for acute musculoskeletal pain. The combination has limited apparent patent exclusivity, while its principal barriers are regulatory compliance, aspirin safety, anticholinergic tolerability, and competition from inexpensive single-agent and combination analgesics.

Orphenadrine Citrate Aspirin Caffeine: Excipient Strategy and Commercial Opportunities

What is the orphenadrine citrate aspirin caffeine combination?

Orphenadrine citrate aspirin caffeine is a fixed-dose oral analgesic and skeletal-muscle-relaxant combination. The conventional tablet strength associated with Norgesic and generic equivalents contains:

Active ingredient	Conventional tablet amount	Functional role
Orphenadrine citrate	25 mg	Centrally acting skeletal muscle relaxant with anticholinergic properties
Aspirin	385 mg	Analgesic and anti-inflammatory salicylate
Caffeine	30 mg	Analgesic adjuvant and stimulant

The combination is indicated for painful musculoskeletal conditions in which muscle spasm and pain occur together. The product is not positioned as a disease-modifying therapy. Its commercial rationale is convenience through combination dosing and the potential for caffeine to enhance analgesic activity.

The product requires a conventional immediate-release tablet platform. A modified-release design would introduce unnecessary regulatory and clinical complexity unless the sponsor pursued a new formulation under a 505(b)(2) pathway.

What excipient strategy is appropriate for this tablet?

The preferred excipient strategy is a robust, low-cost immediate-release formulation that controls aspirin stability, supports tablet strength, and avoids unnecessary excipient complexity.

Recommended excipient architecture

Formulation function	Suitable excipient classes	Commercial rationale
Diluent	Microcrystalline cellulose, anhydrous lactose, dibasic calcium phosphate	Provides tablet mass and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Supports mechanical strength at relatively low tablet weight
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Promotes rapid breakup and consistent dissolution
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports high-speed compression
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Colorant	Approved lake color or iron oxide system	Supports product identification and brand differentiation
Film coating	Hypromellose, polyethylene glycol, titanium dioxide where permitted	Improves swallowability, appearance, and handling

A direct-compression formulation is commercially attractive if the active-particle properties and blend uniformity are suitable. Wet granulation may provide better control of segregation and content uniformity, particularly because the formulation contains three actives with materially different dose levels and physical properties.

What is the main formulation challenge?

The main technical problem is not total drug loading. It is content uniformity and physical stability across a multi-active blend.

Aspirin is present at a substantially higher mass than orphenadrine citrate and caffeine. The formulation must prevent segregation during blending, transfer, compression, and packaging. Caffeine can also affect powder flow and blend behavior, while low-dose orphenadrine citrate presents the highest content-uniformity risk.

A practical development sequence is:

1. Characterize particle-size distribution, density, morphology, and moisture sensitivity for each active.
2. Use geometric dilution or an ordered blending process for orphenadrine citrate and caffeine.
3. Evaluate direct compression against dry granulation.
4. Measure blend and tablet content uniformity at beginning, middle, and end of compression runs.
5. Test aspirin degradation products, including salicylic acid, under heat and humidity stress.
6. Confirm rapid dissolution for all three actives.

How should aspirin stability influence excipient selection?

Aspirin is susceptible to hydrolysis, particularly in the presence of moisture. The formulation should therefore limit water exposure and use packaging that provides a strong moisture barrier.

Preferred controls include:

• Low-moisture excipients.
• Avoidance of unnecessary aqueous processing.
• Controlled granulation endpoint if wet granulation is used.
• Low-residual-moisture packaging components.
• High-barrier blister packaging or tightly closed moisture-resistant bottles.
• Stability testing for aspirin, salicylic acid, caffeine, and orphenadrine-related substances.

An anhydrous or low-moisture formulation may offer a clearer commercial advantage than a complex coating system. The coating should not be treated as the primary stability solution if the core tablet absorbs moisture during storage.

A sponsor should also assess excipient compatibility with aspirin. Alkaline microenvironments may accelerate aspirin degradation. The formulation development program should test pH-sensitive interactions rather than relying only on conventional accelerated stability data.

What excipients are most suitable for commercial-scale manufacturing?

Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate are established oral-solid-dose excipients with broad supplier availability. They support a conventional supply chain and generally simplify scale-up.

Povidone and pregelatinized starch may be preferable where the formulation requires stronger granules or improved compactability. Sodium stearyl fumarate can be evaluated where magnesium stearate over-lubrication reduces tablet hardness or slows dissolution.

The final selection should prioritize:

• Consistent global supply.
• Multiple qualified sources.
• Low moisture contribution.
• Compatibility with aspirin.
• Reliable performance at commercial tablet speeds.
• Low risk of nitrosamine or elemental-impurity concerns from the complete supply chain.
• Suitability for the intended markets and compendial standards.

Excipient novelty has limited value for this product unless it produces a measurable improvement in stability, dissolution, swallowability, or manufacturing yield.

What formulation patents protect or could protect this product?

The underlying three-active combination is an old pharmaceutical concept and is unlikely to offer a meaningful new-composition patent position by itself. Commercial protection would more likely come from:

• A specific excipient composition.
• A low-moisture formulation with improved aspirin stability.
• A tablet architecture that improves content uniformity.
• A taste-masked or orally disintegrating dosage form.
• A defined particle-size or granulation process.
• A novel packaging and stability combination.
• A clinically differentiated dosing regimen.

A patent directed only to routine use of standard excipients would face a substantial obviousness risk. A stronger formulation patent would need comparative data showing an unexpected result, such as materially lower aspirin degradation, improved dissolution after storage, reduced tablet weight, or improved content uniformity at scale.

The Orange Book status must be evaluated product by product because listed patents, discontinued products, and approved generic applications can change. FDA labeling establishes the active ingredients, dosage form, indications, and warnings, but it does not by itself establish a current blocking patent position. The cited product labeling does not provide a current, enforceable patent estate for the combination.[1][2]

When does this product lose exclusivity?

The relevant exclusivity risk is generally generic competition rather than biosimilar competition. Orphenadrine citrate, aspirin, and caffeine are small-molecule active ingredients, so biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply.

The main market-entry pathways are:

Market-entry route	Relevance
ANDA	Likely route for a therapeutically equivalent immediate-release generic with the same active ingredients, strength, route, and dosage form
505(b)(2) NDA	Relevant for a materially different formulation, delivery system, dosing regimen, or clinical positioning
New NDA	Unlikely unless the sponsor creates a substantially new therapeutic product
OTC switch	Possible only through a separate FDA regulatory strategy and would require appropriate labeling and safety support

Paragraph IV litigation is possible if an Orange Book-listed patent covers an approved reference product. For an older combination with no clearly established active composition patent in the sources cited, the principal risk is expected to arise from product-specific listing analysis, formulation patents, or use patents rather than from a foundational active-ingredient patent.

What is the FDA regulatory status of orphenadrine citrate aspirin caffeine?

The combination is an FDA-regulated prescription oral product. Its label includes important restrictions associated with all three active ingredients.

Orphenadrine citrate carries anticholinergic risks, including dry mouth, blurred vision, urinary retention, tachycardia, confusion, and potential impairment. Aspirin carries gastrointestinal bleeding, ulceration, hypersensitivity, renal, and bleeding risks. Caffeine can cause nervousness, insomnia, tremor, palpitations, and dose-related intolerance.

The formulation and labeling must address:

• Aspirin hypersensitivity and salicylate intolerance.
• Bleeding risk and concomitant anticoagulant or antiplatelet therapy.
• Peptic ulcer disease.
• Renal or hepatic impairment.
• Glaucoma and urinary retention risk from anticholinergic activity.
• Older adults, who may be more sensitive to confusion and anticholinergic effects.
• Concomitant caffeine consumption.
• Use in children and adolescents with viral illness because of aspirin-associated safety concerns.

These warnings limit broad consumer positioning and favor a targeted prescription-market strategy.

What commercial opportunities exist for this combination?

Generic or authorized-generic supply

The most direct opportunity is a reliable generic product with:

• Competitive tablet cost.
• High service levels.
• Multi-source active-ingredient procurement.
• Stable aspirin impurity profile.
• Consistent tablet appearance.
• Unit-dose packaging for institutional customers.

The market is likely price-sensitive. Manufacturing efficiency and supply reliability may produce more value than premium branding.

Reformulated prescription product

A reformulated product could target one or more specific limitations:

• Lower tablet mass.
• Improved swallowability.
• Reduced aspirin degradation during storage.
• Better tablet robustness.
• Reduced caffeine-related intolerance through alternative strength ratios.
• Scored tablets for dosing flexibility.
• Blister packaging for adherence and moisture control.

Changing the active ratios would generally create a more complex regulatory program and may eliminate the simplest ANDA pathway.

Regional and institutional markets

Potential customers include:

• Primary-care prescribers treating acute musculoskeletal pain.
• Orthopedic and sports-medicine practices.
• Emergency and urgent-care settings.
• Workers’ compensation formularies.
• Hospital outpatient pharmacies.
• Long-term-care facilities, subject to anticholinergic and aspirin safety considerations.

Institutional buyers will prioritize acquisition price, back-order performance, packaging efficiency, and dosage-form familiarity.

Combination-therapy positioning

The product may retain a niche where prescribers want a single prescription covering pain and muscle spasm. Its commercial disadvantage is that clinicians can separately titrate a muscle relaxant and analgesic. Combination positioning is strongest where convenience and short-course treatment are more important than flexible dosing.

How does this product compare with competing therapies?

Therapy	Main advantage	Main limitation versus orphenadrine-aspirin-caffeine
Orphenadrine alone	Allows independent analgesic selection	Does not provide aspirin or caffeine
Cyclobenzaprine	Familiar muscle-relaxant option	Sedation and anticholinergic effects; no fixed analgesic component
Methocarbamol	Broad generic availability	No aspirin or caffeine component
Carisoprodol	Rapid symptomatic effect	Abuse, dependence, and controlled-substance concerns
NSAID plus muscle relaxant	Flexible prescribing	Requires multiple products and may increase gastrointestinal or renal risk
Acetaminophen combinations	Avoids aspirin-related bleeding risk	May provide less anti-inflammatory activity
Topical NSAIDs	Lower systemic exposure	Less suitable for generalized or deeper muscle pain

The fixed-dose product is most differentiated by its combination of a salicylate analgesic, caffeine, and orphenadrine. That differentiation is clinically recognizable but commercially weak if pricing is not competitive.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate. The actives are established, and the dosage form is conventional. The main execution risks are:

• Blend segregation.
• Low-dose orphenadrine uniformity.
• Aspirin hydrolysis.
• Dissolution changes after lubrication.
• Tablet capping or lamination.
• Color and imprint consistency.
• Stability failures under humid conditions.
• Supply interruptions for active pharmaceutical ingredients.

Intellectual-property barriers appear lower than manufacturing and regulatory barriers for a conventional tablet. A sponsor seeking defensible protection should focus on data-supported formulation attributes rather than broad claims covering routine excipient combinations.

Geographic coverage will depend on separate national registrations. FDA approval does not establish approval in Canada, Europe, Japan, or emerging markets. Aspirin labeling, pediatric restrictions, prescription status, and combination-product requirements vary by jurisdiction.

What patent litigation or settlement risks affect the product?

No specific active Paragraph IV litigation or settlement agreement is established in the sources cited for this combination. The practical diligence question is whether a current reference product has Orange Book-listed patents and whether any later-approved formulation or method-of-use patent remains enforceable.

For a conventional generic launch, the risk hierarchy is:

1. Current Orange Book listing for the reference product.
2. Patent certifications required by the ANDA.
3. Any listed formulation or method-of-use patent.
4. Product-specific exclusivity periods.
5. Litigation-triggered 30-month stay exposure.
6. State or federal commercial disputes involving labeling, supply, or substitution.

Because the core actives are old, a new entrant is more likely to face regulatory and market-access issues than a fundamental composition-of-matter challenge.

What is the revenue exposure and launch outlook?

Revenue potential is likely niche and generic-led. The addressable opportunity depends on current prescription volume, active manufacturer count, reimbursement, and whether the reference product remains commercially available. Those metrics are not established in the cited FDA labeling and should not be inferred from historical brand recognition.

A conventional generic launch could succeed with:

• Low-cost domestic or qualified offshore manufacturing.
• Two or more active-ingredient sources.
• Moisture-protective packaging.
• A complete stability package.
• Reliable wholesaler fulfillment.
• A focused institutional sales strategy.

A premium reformulation would require evidence that payers, prescribers, or patients value the improvement. Without clinical or stability differentiation, a higher price would be difficult to defend against established generics and separate-component prescribing.

Key Takeaways

• Orphenadrine citrate aspirin caffeine is best approached as a generic or targeted reformulation opportunity.
• The conventional product contains 25 mg orphenadrine citrate, 385 mg aspirin, and 30 mg caffeine per tablet.
• Moisture control and aspirin stability are central formulation priorities.
• Content uniformity is the main manufacturing challenge because the three actives differ in dose and physical properties.
• Standard excipients are commercially preferable unless a novel system produces a demonstrated performance advantage.
• Biosimilar competition is irrelevant because the product contains small-molecule active ingredients.
• A conventional ANDA is likely more efficient than a 505(b)(2) strategy for an equivalent immediate-release tablet.
• Patent value is more likely to arise from a proven formulation or process improvement than from the old active-ingredient combination.
• Commercial differentiation should focus on supply reliability, packaging, tablet quality, and targeted prescription use.
• Current Orange Book listings, exclusivity, Paragraph IV activity, and launch timing require product-specific FDA database review.

FAQs

Can orphenadrine citrate aspirin caffeine be developed as an extended-release tablet?

Yes, but an extended-release product would require a new formulation strategy, dissolution profile, stability program, and likely a 505(b)(2) or NDA pathway. It would not be the simplest route for an equivalent generic.

Is caffeine necessary in the formulation?

Caffeine is part of the established combination and may enhance analgesic activity, but it also creates tolerability concerns. Removing or changing caffeine would likely create a different regulatory product rather than a straightforward equivalent.

Which packaging is best for aspirin-containing combination tablets?

A high-barrier blister or tightly closed moisture-resistant bottle is generally preferable. Packaging selection should be supported by comparative stability data for aspirin degradation and tablet performance.

Can a sponsor patent a new excipient blend for this product?

Possibly, but broad claims using standard excipients would face patentability challenges. A stronger filing would link the composition to measured improvements in stability, dissolution, content uniformity, or manufacturing performance.

Is an authorized generic strategy attractive for this combination?

It can be attractive where a reference-product owner controls distribution or where a manufacturer can secure a supply agreement. The economics depend on current prescription demand, reference-product status, channel access, and the number of competing generic suppliers.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Orphenadrine citrate, aspirin, and caffeine tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format of an ANDA. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs

4. U.S. Food and Drug Administration. (2024). Approved drug product exclusivity and patent information. https://www.fda.gov/drugs/drug-approvals-and-databases

5. U.S. Food and Drug Administration. (2023). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm